Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 14/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.48 |
| ▸ | AR | P10275 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8768109 | 0.89 | PGR (0.47) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL8536387 | 0.89 | PGR (0.51) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL8536181 | 0.89 | PGR (0.49) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL9019805 | 0.85 | PGR (0.35) | PGRNR3C1ARCYP3A4 | |
| SCHEMBL9019827 | 0.85 | NR3C1 (0.59) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL8538113 | 0.84 | PGR (0.47) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5498124 | 0.84 | PGR (0.49) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL8424666 | 0.83 | PGR (0.71) | PGRNR3C1ARCYP3A4 | |
| SCHEMBL8768805 | 0.83 | PGR (0.55) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL9019768 | 0.83 | PGR (0.68) | PGRNR3C1ARCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | claimed |
| EP-0404283-A2 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-27 | — | — | EP | claimed |
| US-5843933-A | 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| US-5728689-A | ANTIGESTAGENIC EFFECT | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0404283-A2 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-27 | — | — | EP | disclosed |